Chlamydia serotypes — sometimes called serovars — are antigenically distinct variants of the bacterium *Chlamydia trachomatis*. Understanding which serotype is involved helps clinicians make sense of why the same bacterial species can cause conditions as different as a tropical eye disease, a common sexually transmitted infection and a rare invasive condition called lymphogranuloma venereum (LGV). This article explains what chlamydia bacteria are, how serotypes are classified, what diseases they are associated with, and how serology differs from the tests routinely used to diagnose an active *C. trachomatis* infection.
What Are Chlamydia Bacteria?
*Chlamydia* is a genus of obligate intracellular bacteria, meaning they can only replicate inside the living cells of a host organism. They are unable to produce their own energy and depend entirely on the metabolic machinery of the cells they infect. Several species exist within this genus, but two are most clinically significant in human medicine: *Chlamydia trachomatis* and *Chlamydia pneumoniae*.
The key point is that these are separate bacterial species associated with entirely different clinical conditions. *C. trachomatis* is associated with sexually transmitted infections, trachoma (an infectious eye disease) and LGV, depending on the specific serotype involved. *C. pneumoniae*, by contrast, is primarily associated with respiratory tract infections, including community-acquired pneumonia, bronchitis and sinusitis.
A third species, *Chlamydia psittaci*, causes psittacosis (a respiratory illness acquired from birds), though this is far less commonly encountered in clinical practice in the UK.
Because these species differ in both their biology and their disease associations, it is important not to conflate them — a distinction this article will return to explicitly.
What Are Chlamydia Serotypes?
A serotype (or serovar) is a subclassification of a bacterial species based on the antigens — typically surface proteins — that the bacterium expresses. When your immune system encounters a bacterium, it produces antibodies targeting those specific surface antigens. Different serotypes of the same species carry distinguishable antigenic profiles, which is why laboratory scientists and clinicians can differentiate between them.
In the context of *Chlamydia trachomatis*, serotypes are differentiated largely on the basis of variation in the major outer membrane protein (MOMP), which is encoded by the *ompA* gene. These differences are not merely academic: distinct serotype groups of *C. trachomatis* are associated with distinct anatomical sites of infection and distinct clinical diseases.
Understanding serotypes matters because it helps explain:
Related Test
Full Blood Count
Complete blood analysis • Same-day appointments • UKAS-accredited lab
Chlamydia Serotypes and Disease
*Chlamydia trachomatis* is traditionally divided into three broad groups of serotypes, each associated with different diseases and clinical presentations. The table below provides a useful overview.
| Serotype Group | Associated Disease(s) | Primary Site(s) of Infection |
|---|---|---|
| A, B, Ba, C | Trachoma (ocular infection) | Conjunctiva (eyes) |
| D, E, F, G, H, I, J, K | Urogenital chlamydia; neonatal conjunctivitis; some ocular infections | Urogenital tract; eyes (neonatal) |
| L1, L2, L2a, L3 | Lymphogranuloma venereum (LGV) | Lymphatic system; anorectal tract; urogenital tract |
It is worth noting that classification nomenclature can vary slightly across different published references and laboratory reporting conventions. These groupings represent the most widely cited clinical distinctions rather than a fully exhaustive account of every possible presentation.
Serotypes A–C: The Trachoma Group
Serotypes A, B, Ba and C of *Chlamydia trachomatis* are associated with trachoma, a chronic infectious eye disease and one of the leading preventable causes of blindness worldwide. Trachoma is rare in the United Kingdom but remains a major public health concern in parts of sub-Saharan Africa, South Asia and the Middle East.
Trachoma spreads through direct or indirect contact with eye and nasal discharge from infected individuals, often facilitated by poor access to clean water and sanitation. Flies can also act as mechanical vectors in endemic areas.
In trachoma, repeated infections of the conjunctiva — the membrane lining the inside of the eyelid and covering the white of the eye — trigger a chronic inflammatory response. Over time, this causes scarring of the inner eyelid (trachomatous trichiasis), where the eyelashes turn inward and repeatedly abrade the cornea. If left untreated, this can result in corneal opacity and irreversible blindness.
Importantly, trachoma caused by serotypes A–C differs substantially from genital chlamydia infection. It is not a sexually transmitted infection, and the serotypes responsible for trachoma are not typically associated with urogenital disease. If you have concerns about possible chlamydia exposure through sexual contact, trachoma serovars are not the relevant group to be concerned about.
Serotypes D–K: Urogenital Chlamydia
Serotypes D through K are the group most commonly associated with sexually transmitted *Chlamydia trachomatis* infections in the UK and other high-income countries. These are the serovars responsible for the genital chlamydia infections routinely discussed in sexual health services.
In England, chlamydia is the most commonly diagnosed bacterial sexually transmitted infection, and the NHS National Chlamydia Screening Programme specifically targets sexually active people under 25 years of age. Infections with D–K serotypes typically involve the:
A critical point is that many *C. trachomatis* infections in the D–K group produce no symptoms. Estimates suggest that around 50–70% of women and up to 50% of men with genital chlamydia may experience no noticeable symptoms at all. Asymptomatic infection is one of the key reasons routine testing is recommended following potential exposure.
Neonatal conjunctivitis (ophthalmia neonatorum) can also result from D–K serotypes, transmitted to the neonate during passage through an infected birth canal.
Symptoms, where they do occur, can include unusual discharge, pelvic or testicular discomfort, pain on urination, or intermenstrual bleeding — but these symptoms are non-specific and do not reliably indicate a particular serotype. Anyone experiencing possible symptoms or with potential exposure should seek clinical assessment rather than self-diagnosing based on symptoms alone.
Serotypes L1–L3: Lymphogranuloma Venereum (LGV)
Serotypes L1, L2 (including the L2a variant) and L3 of *Chlamydia trachomatis* cause lymphogranuloma venereum (LGV), a more invasive form of chlamydial infection that behaves quite differently from the urogenital infections caused by serotypes D–K.
LGV serovars are particularly adept at infecting macrophages — immune cells — allowing them to penetrate deeper tissues and spread via the lymphatic system. This invasive behaviour explains why LGV produces clinical features not typical of standard genital chlamydia.
LGV is more commonly reported in men who have sex with men (MSM) in the UK, and the UK Health Security Agency (UKHSA) has published epidemiological reports describing outbreaks in this population over recent years. Rectal LGV, presenting with proctitis (inflammation of the rectum), is a particularly recognised clinical picture.
The clinical course of LGV is often described in stages:
1. Primary stage: A small, transient genital ulcer or papule that may go unnoticed.
2. Secondary stage: Swollen, painful lymph nodes (buboes), particularly in the groin, or severe proctitis with mucous or bloody rectal discharge.
3. Tertiary stage: If untreated, chronic inflammation can lead to significant complications including genital elephantiasis (lymphoedema) or rectal stricture.
When LGV is clinically suspected — particularly in someone presenting with proctitis who has had relevant exposure — specialised laboratory testing is needed to differentiate LGV from non-LGV *C. trachomatis* infection, as treatment duration typically differs.
Chlamydia Serology: What Does It Mean?
Chlamydia serology refers to blood tests that detect antibodies produced by the immune system in response to *Chlamydia trachomatis* infection, rather than detecting the bacterium itself. The most commonly measured antibodies in chlamydia serology include IgG, IgM and IgA antibodies.
What Does a Positive Chlamydia Serology Result Indicate?
A positive chlamydia serology result means that the immune system has at some point mounted a response to *C. trachomatis* — but this does not by itself confirm an active or current infection. Antibodies can persist in the bloodstream for months or even years after an infection has resolved, either spontaneously or following treatment. A positive serology result may therefore reflect:
Equally, a negative serology result does not rule out current infection, particularly if the infection is recent and the immune response is still developing.
Is Chlamydia Serology Used Routinely to Diagnose Genital Infection?
No. Chlamydia serology is not routinely recommended for diagnosing uncomplicated genital *C. trachomatis* infection. Guidance from bodies such as the British Association for Sexual Health and HIV (BASHH) does not advocate serology as a standard diagnostic tool for urogenital chlamydia.
Serology has a limited role in specific clinical contexts, such as investigating possible pelvic inflammatory disease, epididymo-orchitis, or in research and epidemiological settings. It is important not to confuse antibody testing with the nucleic acid amplification test (NAAT), which is a completely different type of test and the standard method for diagnosing active *C. trachomatis* infection.
How Is *Chlamydia Trachomatis* Diagnosed?
Nucleic acid amplification testing (NAAT) is the recommended method for diagnosing an active *Chlamydia trachomatis* infection. NAAT works by detecting the genetic material (DNA or RNA) of the bacterium itself, making it highly sensitive and specific for identifying a current infection.
The appropriate specimen for NAAT depends on the likely site of infection and the clinical circumstances:
When LGV is clinically suspected, standard NAAT will confirm *C. trachomatis* infection, but an additional genotyping step is required to identify the L-serotype and distinguish LGV from non-LGV infection. Not all standard laboratory panels automatically perform this genotyping, so clinical information should be provided to the laboratory when LGV is suspected.
The choice of test, specimen type and laboratory methodology should always reflect the clinical presentation, the possible site of exposure and professional guidance. If you have concerns about possible exposure or symptoms, a sexual health clinician is best placed to advise on the most appropriate assessment.
For broader health assessment that may support your sexual health, you may find our health screening services relevant, or you can book a private blood test for assessment in a confidential setting.
Can *Chlamydia Pneumoniae* Cause *Chlamydia Trachomatis* Infection?
No. *Chlamydia pneumoniae* and *Chlamydia trachomatis* are entirely separate bacterial species. One species cannot transform into or cause infection by the other. They are related by being in the same bacterial genus, much as different mammal species are related by belonging to the same class — but they are biologically distinct organisms with different genetic make-up, different disease associations and different routes of transmission.
A person can theoretically have infections caused by both species simultaneously, but they are independent infections acquired through different routes. Testing for one species does not diagnose or rule out infection with the other.
When to Seek Medical Advice
Anyone who has had a potential exposure to a sexually transmitted infection, is experiencing symptoms that may indicate a chlamydial infection, or has received a test result they are uncertain about should seek appropriate clinical advice.
In the UK, sexual health services are available through NHS sexual health clinics (sometimes called GUM clinics), GP surgeries and online services. If you are considering a private test, it is important to understand what the test is measuring and to ensure results are interpreted in the right clinical context. Private testing can support timely access and confidentiality, but it does not replace the clinical assessment and expertise that a sexual health specialist can provide.
If you have concerns, please do not rely on internet research alone. Contact an appropriate healthcare professional or sexual health service.
You can find details about our private testing services and blood test prices on the Private Blood Tests London website.
Frequently Asked Questions
What are chlamydia serotypes?
Chlamydia serotypes — also called serovars — are antigenically distinct variants of *Chlamydia trachomatis*, differentiated by the surface antigens they express, primarily the major outer membrane protein. Different serotypes are associated with different diseases and anatomical sites of infection.
Which chlamydia serotypes cause trachoma?
Serotypes A, B, Ba and C of *Chlamydia trachomatis* are associated with trachoma, a chronic infectious eye disease that is a leading cause of preventable blindness in some regions of the world. These serotypes are not associated with sexually transmitted genital infections.
What is the difference between serotypes A–C and D–K?
Serotypes A–C are associated with trachoma, a non-sexually transmitted ocular infection. Serotypes D–K are associated with urogenital chlamydia, the most commonly diagnosed bacterial STI in the UK, as well as neonatal conjunctivitis in some cases.
Which chlamydia serotypes cause LGV?
Serotypes L1, L2 (including the variant L2a) and L3 cause lymphogranuloma venereum (LGV), a more invasive form of *C. trachomatis* infection that affects lymphatic tissues and, commonly, the rectum.
What does chlamydia serology mean?
Chlamydia serology refers to blood tests that detect antibodies produced in response to *C. trachomatis* infection. It measures the immune system's response to the bacterium rather than detecting the bacterium itself.
What does a positive chlamydia serology result mean?
A positive chlamydia serology result indicates that the immune system has encountered *C. trachomatis* at some point. It does not confirm an active current infection, as antibodies can persist long after infection has resolved. The result must be interpreted by a clinician in context.
Is chlamydia serology used to diagnose active genital infection?
No. Chlamydia serology is not recommended as a routine test for diagnosing uncomplicated genital *C. trachomatis* infection. NAAT (nucleic acid amplification testing) is the standard method for detecting an active infection.
How is *Chlamydia trachomatis* diagnosed?
NAAT is the primary method used to diagnose active *C. trachomatis* infection. Depending on the possible site of infection, appropriate specimens may include a first-catch urine sample, a vulvovaginal swab, a rectal swab or a pharyngeal swab.
Is *Chlamydia pneumoniae* the same as *Chlamydia trachomatis*?
No. They are distinct bacterial species within the same genus. *C. pneumoniae* causes respiratory infections and is not sexually transmitted. *C. trachomatis* causes urogenital infections, trachoma and LGV depending on the serotype. One cannot cause the other.
Can a standard chlamydia NAAT identify the infecting serotype?
Standard NAAT confirms the presence of *C. trachomatis* but does not routinely identify the specific serotype. When LGV is suspected, additional genotyping of a positive sample is required to confirm L-type serovars. This should be flagged to the laboratory at the time of testing.
Can someone have chlamydia with no symptoms?
Yes. A significant proportion of *C. trachomatis* infections — particularly those caused by D–K serotypes — produce no symptoms at all. This is one reason routine testing is recommended following possible exposure, even in the absence of symptoms.
Do chlamydia serotypes affect how the infection is treated?
For most urogenital *C. trachomatis* infections (D–K serotypes), treatment follows standard antibiotic guidance, typically involving doxycycline or azithromycin as directed by a clinician. LGV (L1–L3 serotypes) generally requires a longer course of treatment. Treatment decisions must always be made by a qualified healthcare professional based on the individual's circumstances. This article does not constitute prescribing advice.
Medical References
1. NHS England — Chlamydia: Overview and screening. www.nhs.uk/conditions/chlamydia
2. British Association for Sexual Health and HIV (BASHH) — 2018 UK National Guideline for the Management of Infection with *Chlamydia trachomatis*. www.bashh.org
3. British Association for Sexual Health and HIV (BASHH) — Lymphogranuloma Venereum Guideline. www.bashh.org
4. UK Health Security Agency (UKHSA) — Lymphogranuloma venereum (LGV): guidelines and epidemiological data. www.gov.uk/government/collections/lymphogranuloma-venereum-lgv-guidance-data-and-analysis
5. UK Health Security Agency (UKHSA) — Sexually transmitted infections and chlamydia screening in England: health protection report. www.gov.uk
6. World Health Organization (WHO) — Trachoma fact sheet. www.who.int/news-room/fact-sheets/detail/trachoma
7. Centers for Disease Control and Prevention (CDC) — *Chlamydia trachomatis* infections: diagnostic considerations and clinical guidance. www.cdc.gov/std/chlamydia
8. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (9th edition) — Chapter on *Chlamydia trachomatis* (Elsevier).
9. Stephens RS — *The cellular paradigm of chlamydial pathogenesis*, Trends in Microbiology, 2003.
10. Public Health England — PHE National Chlamydia Screening Programme guidance documentation (archived).
This article is intended for informational purposes only and does not constitute medical advice, diagnosis or treatment. If you have concerns about a possible infection or test result, please consult a qualified healthcare professional or sexual health service.